493 KB16 KB199220252014Debeljak, MarušaDolžan, VitaErčulj, NinaFaganel, BarbaraJazbec, Janezštevilka:3letnik:48str. 289-292, VISSN:1318-2099COBISSID:31525337URN:URN:NBN:SI:doc-OP7JC2NNenAssociation of Radiology and OncologyRadiology and oncology (Ljubljana)childhoodne-Hodgkinov limfomnon-Hodgkin lymphomaotroštvopolimorfizempolymorphismThe influence of folate pathway polymorphisms on high-dose methotrexaterelated toxicity and survival in children with non-Hodgkin malignant lymphoma|Background. We evaluated the influence of folate pathway polymorphisms on high-dose methotrexate (HD-MTX) related toxicity in paediatric patients with T-cell non-Hodgkin lymphoma (NHL). Patients and methods. In total, 30 NHL patients were genotyped for selected folate pathway polymorphisms. Results. Carriers of at least one MTHFR 677T allele had significantly higher MTX area under the time-concentration curve levels at third MTX cycle (P = 0.003). These patients were also at higher odds of leucopoenia (P = 0.006) or thrombocytopenia (P = 0.041) and had higher number of different HD-MTX-related toxicity (P = 0.035) compared to patients with wild-type genotype. Conclusions. Our results suggest an important role of MTHFR 677C>T polymorphism in the development of HD-MTXrelated toxicity in children with NHLTEXTznanstveno časopisjejournalsSlovenian National E-content AggregatorNational and University Library of SloveniaDruštvo radiologije in onkologije